Investigating lysosomal dysfunction in Fabry disease using induced pluripotent stem cell-derived podocytes

Abstract

Aims: This study used induced pluripotent stem cell-derived podocytes from a Fabry disease (FD) patient carrying the p.Met284Thr pathogenic variant as an in vitro model to investigate lysosomal abnormalities driving cell pathology. Proteomic analysis was used to assess changes in lysosomal protein abundance in FD podocytes compared to controls. Additionally, temporal changes in lysosome number in FD podocytes were analyzed using automated live-cell imaging.

Methods: Label-free mass spectrometry proteomics was performed on FD podocytes at day 10 of differentiation compared to controls. For live-cell imaging, cultured podocytes were transfected with CellLight Lysosomes-GFP and Plasma Membrane-CFP, and then visualized and quantified on days 10 and 20 post-differentiation using a Perkin Elmer Phenix High Content Screening Microscope.

Results: Proteomic analysis showed dysregulation of glycosphingolipid metabolism proteins, including decreased galactosidase alpha (GLA; P < 0.01) and increased galactosylceramidase and glucosylceramidase (P < 0.01) in FD podocytes. Lysosomal proteins were enriched, with a significant increase in cathepsin B (P < 0.001) and a decrease in lipase A (P < 0.01). Furthermore, the dysregulation of proteins involved in cell cycle regulation and growth signaling pathways, such as polo-like kinase 1 (PLK1; P < 0.0001) and proto-oncogene tyrosine-protein kinase Src (SRC; P < 0.01), suggested broader impacts on cellular processes. Temporal live-cell imaging revealed a significant increase in lysosome number in day 20 FD podocytes compared to day 10 FD podocytes and controls (P < 0.01).

Conclusions: These findings collectively suggest that FD podocytes undergo progressive lysosomal impairment, which may contribute to cellular dysfunction and disease progression. These proof-of-concept findings lay a foundation for future research on targeted FD therapies using high-throughput screening and advanced analytical techniques.

Keywords

Fabry disease / lysosomes / podocytes / induced pluripotent stem cells / proteomics / live-cell imaging

References

[1] BokhariSRA,HarizA.Fabry Disease. Treasure Island, FL: StatPearls Publishing; 2025.

[2] ChinSJ.Prevalence of lysosomal storage disorders in Australia from 2009 to 2020.Lancet Reg Health West Pac2022;19:100344 PMCID:PMC8671750

[3] ThurbergBL,ColvinRB.Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.Kidney Int2002;62:1933-46

[4] DelaleuN,StraussP.Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing.Kidney Int2023;104:803-19

[5] BraunF,SellungD.Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.J Clin Invest2023;133:e157782

[6] TalbotA,FletcherJM.A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease.Mol Genet Metab2017;122:121-5

[7] SantostefanoM,GibertoniD.Fabry disease nephropathy: histological changes with nonclassical mutations and genetic variants of unknown significance.Am J Kidney Dis2023;82:581-96.e0

[8] MaruyamaH,MikameM.Effectiveness of plasma lyso-Gb₃ as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.Genet Med2019;21:44-52 PMCID:PMC6363642

[9] LiebauMC,HöpkerK.Dysregulated autophagy contributes to podocyte damage in Fabry's disease.PLoS One2013;8:e63506 PMCID:PMC3656911

[10] WiseAF,BruellS.Fabry disease podocytes reveal ferroptosis as a potential regulator of cell pathology.Kidney Int Rep2025;10:535-48 PMCID:PMC11843119

[11] KimSY,LeeSW.RIPK3 contributes to Lyso-Gb3-induced podocyte death.Cells2021;10:245

[12] NajafianB,SvarstadE,OliveiraJP.Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss.J Am Soc Nephrol2020;31:865-75 PMCID:PMC7191924

[13] TebaniA,DormondO.Deep next-generation proteomics and network analysis reveal systemic and tissue-specific patterns in Fabry disease.Transl Res2023;258:47-59

[14] TebaniA,Abily-DonvalL.A proteomics-based analysis reveals predictive biological patterns in Fabry disease.J Clin Med2020;9:1325

[15] TerHuurne M,LiuNQ.GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.Am J Hum Genet2023;110:1600-5

[16] WiseAF,RicardoSD.The differentiation of human induced pluripotent stem cells into podocytes in vitro.Methods Mol Biol2022;2454:317-25

[17] SongB,JonesCV.The directed differentiation of human iPS cells into kidney podocytes.PLoS One2012;7:e46453 PMCID:PMC3460883

[18] LauRWK,PhanTK.Modelling X-linked alport syndrome with induced pluripotent stem cell-derived podocytes.Kidney Int Rep2021;6:2912-7 PMCID:PMC8589688

[19] AertsJM,KuiperS.Elevated globotriaosylsphingosine is a hallmark of Fabry disease.Proc Natl Acad Sci USA2008;105:2812-7 PMCID:PMC2268542

[20] TaguchiA,MikameM.Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.Mol Genet Metab Rep2023;34:100952 PMCID:PMC9823212

[21] ElsaidHOA,SkandalouE.Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla^-/- zebrafish model of Fabry disease.J Transl Med2023;21:591 PMCID:PMC10478213

[22] Sanchez-NiñoMD,SanzAB,MezzanoS.Lyso-Gb3 activates Notch1 in human podocytes.Hum Mol Genet2015;24:5720-32

[23] BeckM,Hernberg-StåhlE.Twenty years of the Fabry outcome survey (FOS): insights, achievements, and lessons learned from a global patient registry.Orphanet J Rare Dis2022;17:238 PMCID:PMC9208147

[24] MooreDF,BeavisRC.Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.Proc Natl Acad Sci USA2007;104:2873-8

[25] ChimentiC,BoontjeNM.Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.Am J Pathol2008;172:1482-90

[26] BirketMJ,LettieriM.A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology.Stem Cell Rep2019;13:380-93 PMCID:PMC6700557

[27] DeeganPB,GeberhiwotT.Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.Mol Genet Metab2023;138:106963 PMCID:PMC9918698

[28] GuérardN,NordbeckP.Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement.Clin Pharmacol Ther2018;103:703-11